RT Journal Article
T1 Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries
A1 Burgos Blasco, Bárbara
A1 García Feijoo, Julián
A1 Ginés Gallego, Cristina
A1 Perucho González, Lucía
A1 Fernández Vigo, José Ignacio
A1 Martínez De La Casa Fernández-Borrella, José María
A1 Sáenz Francés, Federico
A1 Morales Fernández, Laura
A1 Méndez Hernández, Carmen Dora
AB Purpose: This study aims to evaluate the efficacy and safety of the PreserFlo MicroShunt (Santen, Osaka, Japan) in lowering intraocular pressure (IOP) in childhood glaucoma patients with previous failed glaucoma surgeries.Methods: This is a prospective case review of consecutive PreserFlo procedures performed in childhood glaucoma patients after failed surgeries. Age, sex, diagnosis, and previous glaucoma surgeries, as well as visual acuity, IOP, and treatment in the preoperative visit and all follow-up visits were collected. Outcome measures included IOP reduction from baseline, mean IOP change from baseline at month 6, medication use at 6 months, complications, adverse events, and need for further procedures.Results: Fourteen patients were included, 8 (57%) males and 6 (43%) females; the mean age was 27.5 ± 13.5 years. Nine patients (64%) had at least two trabeculectomies, and 6 patients (43%) had at least one trabeculectomy and a glaucoma drainage implant. The mean IOP change from baseline was 11.3 ± 4.9 mmHg at 12 months. At 12 months, 12 patients (86%) presented ≥ 20% IOP lowering from baseline, and 11 patients (79%) presented ≥ 30%. The mean medication count decreased from 3.9 ± 0.7 (baseline) to 0.7 ± 1.3 (12 months). No intraoperative complications were reported. No adverse events were noted. No secondary filtration surgery was required, although bleb needling was required in one case, 1 month after the surgery.Conclusions: PreserFlo with MMC can be used successfully to treat uncontrolled IOP in childhood glaucoma cases with previous failed surgeries. Larger studies with longer follow-up are needed to further explore the role of the device in resistant childhood glaucoma cases.
PB Springer
SN 0721-832X
YR 2023
FD 2023-05
LK https://hdl.handle.net/20.500.14352/73237
UL https://hdl.handle.net/20.500.14352/73237
LA eng
NO Burgos Blasco, B., García Feijoo, J., Ginés Gallego, C. et al. «Efficacy and Safety of the PreserFlo Implant with Mitomycin C in Childhood Glaucoma after Previous Failed Glaucoma Surgeries». Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 261, n.o 5, mayo de 2023, pp. 1349-57. DOI.org (Crossref), https://doi.org/10.1007/s00417-022-05939-5.
DS Docta Complutense
RD 22 ago 2024